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ummary
bjective: C-reactive protein (CRP) has been associated with disease progression in patients with osteoarthritis (OA), but the reasons for this
emain unclear. We hypothesized that higher CRP would be related to local inﬂammatory ﬁndings in the joints of patients with OA.
ethods: Plasma and synovial membrane specimens from 54 OA patients undergoing total hip or knee arthroplasty or arthroscopy were
btained. Synovial ﬂuid was obtained from 25 of these patients. Hematoxylin and eosin stained synovial membrane sections were scored
or degree of inﬂammatory cell inﬁltration. Plasma high-sensitivity CRP (hsCRP) levels, and serum and synovial ﬂuid interleukin (IL)-6 and
L-1b levels were measured by enzyme-linked immunosorbent assay.
esults: Fifty-seven percent of patients with idiopathic OA had inﬂammatory inﬁltrates within the synovial membrane. The mean hsCRP level in
atients with inﬂammatory inﬁltrates was signiﬁcantly higher than those without inﬂammation (4.7 5.0 mg/L vs 1.7 3.6 mg/L, P¼ 0.003).
here were signiﬁcant correlations between hsCRP levels and synovial ﬂuid IL-6 (r¼ 0.64, P¼ 0.0006), degree of synovial inﬂammatory
nﬁltration (r¼ 0.43, P¼ 0.002), and body mass index (r¼ 0.31, P¼ 0.02). Multivariate analysis indicated that only degree of inﬂammatory
nﬁltrate was signiﬁcantly associated with hsCRP level (P¼ 0.026).
onclusion: These results suggest that systemic hsCRP levels reﬂect synovial inﬂammation in OA patients, perhaps by means of synovial
L-6 production. Future studies are needed to clarify how these inﬁltrates and their products may contribute to disease pathogenesis.
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SocietyIntroduction
Traditionally, C-reactive protein (CRP) has been used to
distinguish systemic inﬂammatory disorders such as rheu-
matoid arthritis (RA) from ‘‘noninﬂammatory’’ diseases
such as osteoarthritis (OA). More recently, with the introduc-
tion of high-sensitivity CRP assays (hsCRP), which can de-
tect CRP levels that are an order of magnitude lower than
traditional assays, low-level elevations in CRP have been
observed in diseases where there is a local, low-grade in-
ﬂammatory component. A good example of this is coronary
artery disease, where systemic hsCRP levels have been
shown to be independent predictors of cardiac risk1e4 and
are thought to reﬂect the local inﬂammatory process within
the atheromatous plaque and the vessel wall5,6. However,
beyond being simply a biomarker of inﬂammation, CRP
may reﬂect or contribute to molecular mechanisms of
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Received 17 July 2006; revision accepted 14 October 2006.51disease states. For example, CRP production by hepato-
cytes, the main source of this acute-phase reactant, ap-
pears to be regulated primarily by the proinﬂammatory
cytokines interleukin (IL)-6 and IL-1. Furthermore, CRP it-
self may have important immune-modulating functions as
it has been shown to have multiple roles in innate immune
responses and tissue injury, and has the ability to activate
the complement system, and enhance phagocytosis via op-
sonization (reviewed in Ref.7). The net effect of CRP, at
least in studies of endotoxic shock, appears to be antiin-
ﬂammatory perhaps via enhanced IL-10 production8.
Others7,9 have suggested that lower levels of CRP e as
seen in chronic, subclinical inﬂammatory states such as
obesity and atherosclerosis e might enhance inﬂammation
by activating endothelium, and mediating leukocyte recruit-
ment and proinﬂammatory cytokine synthesis10,11.
Multiple studies have demonstrated that hsCRP is mod-
estly elevated in the plasma of patients with OA compared
to age-matched controls12e15. While hsCRP levels in RA
plasma are typically >15 mg/L, levels in OA typically range
from 3 to 8 mg/L. Additionally, these levels are elevated
when compared with the largest general population study
(n¼ 8592), where the median value for hsCRP was
1.3 mg/L (25the75th percentile: 0.6e2.9)16.
While hsCRP is a nonspeciﬁc marker of inﬂammation and
thus of limited use as a diagnostic marker of OA, recent6
517Osteoarthritis and Cartilage Vol. 15, No. 5studies have demonstrated that hsCRP may have clinical
and prognostic signiﬁcance. Increased hsCRP levels in
sera have been associated with disease progression13,17,18
as well as with clinical severity in OA12. Recently, it was
demonstrated that elevations in hsCRP may reﬂect events
that precede, but ultimately lead to, radiographic progres-
sion in OA14,18. In addition, elevated hsCRP has been
found to be associated with severity of pain in OA15. How-
ever, the mechanistic link between elevated hsCRP levels
and disease activity remains unclear.
The purpose of this study was to investigate the relation-
ship between systemic hsCRP levels and local synovial
membrane inﬂammatory inﬁltrates in OA. We hypothesized
that elevated hsCRP levels would be associated with syno-
vial membrane inﬂammation in patients with idiopathic OA.
In addition, as both IL-6 and IL-1 are known to promote pro-
duction of CRP by hepatocytes, we predicted that elevated
systemic or synovial ﬂuid levels of these two cytokines
might be associated with hsCRP and inﬂammatory inﬁl-
trates in OA.
Materials and methods
PATIENTS
Fifty-four patients with primary OA who were undergoing
total hip or knee arthroplasty or arthroscopy for treatment of
OA were identiﬁed for this study at a single musculoskeletal
specialty hospital. These were consecutive patients pre-
senting for surgery, and all met ACR criteria for idiopathic
OA19. Early OA was deﬁned as a KellgreneLawrence
(KeL)20 score of 2 and no intraoperative evidence of
full-thickness chondral wear. Advanced OA was deﬁned
as KeL score >2 and intraoperative evidence of full-thick-
ness chondral loss. Advanced stage patients satisﬁed
both radiographic and clinical ACR classiﬁcation criteria,
and early patients satisﬁed clinical classiﬁcation criteria.
All patients with congenital malalignment; clinical, intraoper-
ative, or pathologic evidence of previous trauma; avascular
necrosis or inﬂammatory arthropathy were excluded. In ad-
dition, patients with insulin-requiring diabetes, diabetes re-
quiring more than one oral hypoglycemic agent, coronary
artery disease, history of myocardial infarction, history of to-
bacco use within the last 5 years, history of recent trauma or
recent infection were also excluded. Although not a strict
exclusion criteria, none of the patients reported a history
of asthma or were taking any medications for pulmonary
disease, with the exception of one patient who was taking
ipratroprium bromide. These are comorbidities which may
inﬂuence hsCRP levels and thus confound results.
This study was approved by the Institutional Review
Board at Hospital for Special Surgery.
CLINICAL AND RADIOGRAPHIC DATA
Demographic data, current medications, physical ﬁnd-
ings, and intraoperative ﬁndings were recorded. Radio-
graphic KeL scores were determined by a blinded,
experienced musculoskeletal radiologist.
SYNOVIAL TISSUE, JOINT FLUID AND SERUM SAMPLES
Blood and tissue specimens were obtained from the 54
patients at the time of surgery. Six patients underwent
bilateral total joint replacement; in these cases, only the
left side was analyzed. In patients undergoing kneesurgery, synovial samples were obtained from the supra-
patellar region, abutting the cartilage of the femoral troch-
lea. Samples from hip cases were obtained from the
medial femoral neck in a juxtachondral region. All tissue
samples were ﬁxed in formalin, parafﬁn-embedded, and
stained using standard hematoxylin and eosin (H&E) tech-
nique. In addition, synovial ﬂuid specimens were obtained
from 25 patients, all of whom had advanced disease. Sy-
novial ﬂuid aspiration was performed just prior to surgical
arthrotomy. In cases where inadequate amounts of joint
ﬂuid were obtained, the joint was lavaged with 10 cc of
normal saline and re-aspirated. Blood samples were ob-
tained at the beginning of each case and the plasma
was stored at 70C.
ESTABLISHMENT OF SYNOVIAL GRADING SYSTEM
To evaluate the performance of an OA histologic grading
system developed at our institution (E. DiCarlo, unpublished
observations) we reviewed 755 H&E stained synovial tissue
specimens from surgical patients at our institution with both
a clinical (determined by the operating surgeon) and patho-
logic (determined by the evaluating pathologist) diagnosis
of OA. Synovial inﬂammation was graded as absent (only
scattered mononuclear cells), very low grade (0e1 perivas-
cular focal mononuclear cell aggregates per low power
ﬁeld), low grade (multiple perivascular lymphocytic aggre-
gates per low power ﬁeld or detritus associated with giant
cells), or high grade (both perivascular and diffuse lympho-
cytic or lymphoplasmacytic inﬁltrates) (see Fig. 1). Synovial
specimens reviewed were obtained from 297 total hip
arthroplasty cases, 317 total knee arthroplasty cases, and
141 arthroscopic procedures of the knee and included
patients with both primary and secondary OA. The demo-
graphics of the 755 patients included in this retrospective
review are shown in Table I. For the arthroplasty cases,
synovial low- or high-grade inﬂammation was present in
53.2% of hip (48.5% low grade, 4.7% high grade) and
45.4% of knee cases (41.6% low grade, 3.8% high grade).
In arthroscopy cases, low- or high-grade inﬂammation was
present in 42.5% (41.1% low grade, 1.4% high grade).
Overall, there was no difference in the prevalence of syno-
vitis between patients undergoing arthroplasty and those
undergoing arthroscopy. The prevalence of synovitis in
this large cohort of OA patients was consistent with previ-
ous, smaller histologic studies, in which approximately
45e55% of patients with either early or advanced OA
showed evidence of synovial inﬂammation21e23.
After validating our scoring system in this large cohort,
H&E stained sections from the 54 patients in our study
were then classiﬁed using this scoring system. Slides
were reviewed by the same musculoskeletal pathologist
blinded to patient information.
MEASUREMENT OF hsCRP, IL-6, AND IL-1b
An hsCRP enzyme-linked immunosorbent assay (ELISA)
kit (Hemagen Diagnostics, Inc., Columbia, MD) was utilized
with a lower-limit of detection of 0.5 mg/L. Patient plasma
was diluted according to the manufacturer’s directions. As
a control, plasma was also collected from nine nonage-
matched healthy volunteers, and from seven patients with
RA who satisﬁed ACR classiﬁcation criteria.
IL-1b and IL-6 ELISA kits (R&D systems, Minneapolis,
MN) were used to measure both systemic and synovial ﬂuid
cytokine levels. To correct for the unknown dilution of
518 A. D. Pearle et al.: Synovial Inﬂammation and hsCRP in OAFig. 1. Grading scale for synovial inﬂammation in patients with OA. Inﬂammation was graded as absent, very low grade (not shown e only 1
perivascular mononuclear cell aggregate per low power ﬁeld), low-grade (>1 perivascular lymphocytic inﬁltrate per low power ﬁeld or detritus
associated with giant cells), or high grade (perivascular and diffuse lymphocytic or lymphoplasmacytic inﬁltrates).synovial ﬂuid in cases where the joint was lavaged, urea
concentrations in both joint ﬂuid and serum were obtained
and the dilution factor was calculated in accordance with
the technique described by Kraus et al.24.
STATISTICAL ANALYSIS
Nonparametric tests were chosen based on the non-
Gaussian distribution of the data. The ManneWhitney
t-test was performed to evaluate differences between two
groups. When comparing more than two groups, a Kruskale
Wallis test was performed. Fisher’s exact test was used to
compare categorical variables. Spearman’s correlation
coefﬁcients were calculated in the univariate analyses.
Multivariate analysis was performed by using forward step-
wise regression.
Results
PATIENT DEMOGRAPHICS
Fifty-four patients were identiﬁed for the cross-sectional
study. Two patients were excluded from the study: one pa-
tient due to histologic ﬁndings of avascular necrosis and
one patient due to histologic ﬁndings of inﬂammatory ar-
thropathy. The average age of the 52 patients was 63.2
years old (median¼ 64, range 43e79), and 29 (56%)
were females (Table II). Twenty-seven patients had hip
OA while 25 patients had knee OA. Nine of the 52 patients
(17%) were classiﬁed as early OA as described above. The
remaining 43 patients (83%) had advanced OA. All patients
classiﬁed as advanced OA had undergone total joint
Table I
Characteristics of the 755 patients included in the retrospective
review
n Mean age
(range)
Female
(%)
% w/inﬂammation
(low and high grade)
Hip
arthroplasty
297 64.2 (20e89) 56 53.2
Knee
arthroplasty
317 67.8 (23e89) 64 45.4
Knee
arthroscopy
141 55.5 (26e90) 53 42.5arthroplasty. Only one arthroscopy patient was classiﬁed
as advanced OA, based on intraoperative evidence of full-
thickness cartilage wear; the remaining arthroscopy pa-
tients were classiﬁed as early OA.
PREVALENCE OF INFLAMMATORY INFILTRATES IN OA
PATIENTS
Twenty-two patients (43%) with idiopathic OA had no his-
tologic evidence of signiﬁcant synovial inﬂammatory inﬁl-
trates (17 classiﬁed as absent and ﬁve as very low grade;
see Materials and methods), 26 patients (50%) had low-
grade inﬂammatory inﬁltrates, and four patients (7%) had
high-grade inﬂammatory inﬁltrates. There were three pa-
tients with synovial detritus associated with giant cells that
were regarded as having low-grade inﬂammation despite
having no discrete mononuclear cell inﬁltrates.
Due to the small number of patients classiﬁed as either
very low grade (ﬁve patients) or high grade (four patients),
comparisons were made between OA patients without sig-
niﬁcant inﬂammatory inﬁltrates (absent or very low grade)
and those with inﬂammatory inﬁltrates (low and high grade).
As shown in Table II, there was no difference in the preva-
lence of synovial inﬁltrates between the early OA group (5/9
patients or 56%) and the advanced group (25/43 or 58%,
Relative risk (RR)¼ 0.94, P¼ 1.0). The percentage of pa-
tients with synovial inﬁltrates did not differ in patients with
hip or knee OA (RR¼ 1.11, P¼ 0.79). Slightly more women
than men exhibited synovial inﬁltrates (62% of female pa-
tients vs 52% of male patients), but this difference was
not statistically signiﬁcant (RR¼ 1.26, P¼ 0.6). No statis-
tically signiﬁcant differences were seen in age (Manne
WhitneyP¼ 0.39), body mass index (BMI) (P¼ 0.25), or
radiographic score (P¼ 1.00) between patients with and
without synovial inﬁltrates, although there was a nonsigniﬁ-
cant trend toward higher BMI in the group with inﬂammatory
inﬁltrates [Fig. 2(C)], largely due to the effect of one outlier
with a BMI of 60.45.
PLASMA hsCRP LEVELS IN OA PATIENTS AND RELATIONSHIP
TO SYNOVIAL HISTOLOGY AND PATIENT DEMOGRAPHICS
The mean hsCRP level in plasma from all the patients
with OA was 3.4 4.7 mg/L; mean age¼ 63.2 8.1. As ex-
pected, this was signiﬁcantly greater than the hsCRP level
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Characteristics of the 52 patients with OA according to presence or absence of synovial inflammation
Whole group (n¼ 52) þ Inﬂammation (n¼ 30)  Inﬂammation (n¼ 22) P-value
Median age (range) 64 (43e79) 64.00 (43e79) 65.50 (49e78) 0.39*
Median BMI (range) 28.50 (19.9e60.45) 29.63 (19.90e60.45) 27.45 (20.60e39.05) 0.25*
Median KeL score (range) 3 (0e4) 3 (0e4) 3 (0e4) 1.0*
Female 29 (56%) 18 (60%) 11 (50%) 0.6y
Male 23 (44%) 12 (40%) 11 (50%)
Hip 27 (52%) 15 (50%) 12 (54%) 0.79y
Knee 25 (48%) 15 (50%) 10 (46%)
Early 9 (17%) 5 (17%) 4 (18%) 1.0y
Advanced 43 (83%) 25 (83%) 18 (82%)
*P-values from ManneWhitney test. yP-values from Fisher’s exact test.in our small group of young controls (0.29 0.60 mg/L,
P¼ 0.007; mean age 33.2 5.6), but much lower than
levels seen in a group of seven RA patients undergoing
knee or hip arthroplasty (11.2 6.2 mg/L, P¼ 0.002;
mean age 63.5 12.1). Within the OA group, the mean
hsCRP level in the patients with inﬂammatory inﬁltrates
was signiﬁcantly higher compared to the patients without in-
ﬂammation (4.7 5.0 mg/L vs 1.7 3.6 mg/L, P¼ 0.003)
[Fig. 2(A)]. In addition, hsCRP levels had a moderately
strong and statistically signiﬁcant correlation with the de-
gree of inﬂammatory inﬁltration (r¼ 0.42, P¼ 0.0015, Table
III). We found a modest statistically signiﬁcant correlation
between hsCRP level and BMI (r¼ 0.31, P¼ 0.02), consis-
tent with the clinical literature (Table III), but BMI did not cor-
relate with degree of synovial inﬁltration (r¼ 0.18, P¼ 0.20).
There were no signiﬁcant associations between hsCRP
levels and radiographic ﬁndings or age.
IL-6 AND IL-1b LEVELS IN OA PATIENTS AND RELATIONSHIP
TO LOCAL HISTOLOGY
Measurable plasma levels of IL-6weredetected in 36of the
52 OA patients, and were not signiﬁcantly different than con-
trols (1.47 5.2 pg/ml vs 1.01 1.7 pg/ml, P¼ 0.6). Syno-
vial ﬂuid was available for cytokine measurement in
a subset of 25 advanced OA patients. The average synovial
ﬂuid IL-6 level in this subgroup of patients was
88.02 124.74 pg/ml. When these patients were stratiﬁed
according to the presence or absence of synovial inﬂamma-
tion, the mean synovial ﬂuid IL-6 level in the group without in-
ﬂammation was lower (41 42 pg/ml) than that of the group
with inﬂammation (141 169 pg/ml), but the difference was
not statistically signiﬁcant [P¼ 0.12, Fig. 2(B)]. There was,
however, a trend toward a statistically signiﬁcant correlation
between the synovial ﬂuid IL-6 level and the grade of inﬂam-
matory inﬁltrate (r¼ 0.39, P¼ 0.05).
Synovial ﬂuid IL-1b levels did not differ signiﬁcantly be-
tween those patients with and those without synovial inﬂam-
mation (2.5 1.5 pg/ml vs 3.8 2.6 pg/ml, P¼ 0.2).
RELATIONSHIP OF SYSTEMIC HSCRP LEVELS TO SYNOVIAL
FLUID IL-6 AND IL-1b
Patients were dichotomized to a low hsCRP group (de-
ﬁned as hsCRP 3 mg/L) and a high hsCRP group
(>3 mg/L) to allow for comparison of local cytokine levels.
The cutoff level of 3 mg/L was chosen based on two
large-scale population-based studies of hsCRP levels and
cardiovascular risk16,25. Mean synovial ﬂuid IL-6 level in
the high hsCRP group was signiﬁcantly elevated compared
with the low hsCRP group (206.9 176.7 pg/ml vs
35.1 44.6 pg/ml, P¼ 0.001) [Fig. 3(A)]. In contrast, therewas no signiﬁcant difference in synovial ﬂuid IL-1b levels
(3.4 2.2 pg/ml vs 2.9 2.3 pg/ml, P¼ 0.8) between the
two groups. A strong and statistically signiﬁcant correlation
was found between systemic hsCRP levels and synovial
ﬂuid IL-6 level in these 25 OA patients [r¼ 0.64,
P¼ 0.0006, Table III and Fig. 3(B)], but not synovial ﬂuid
IL-1b level (r¼ 0.05, P¼ 0.8).
MULTIVARIATE ANALYSIS
Multiple linear regression analysis was performed to ex-
amine the association between hsCRP levels, BMI, and his-
tologic inﬁltrates. In this model, hsCRP was the dependent
variable, while age, BMI and degree of inﬂammatory inﬁl-
trate were independent covariates. Because hsCRP was
not normally distributed, the data were transformed by tak-
ing the inverse of (hsCRPþ 0.5). Using this model, only de-
gree of inﬂammatory inﬁltrate was signiﬁcantly associated
with hsCRP level (P¼ 0.026). As IL-6 was only measured
in a subset of patients, it could not be entered into this mul-
tivariate model.
Discussion
Most investigations into the pathogenesis of OA have fo-
cused on the degeneration of articular cartilage and associ-
ated changes in the subchondral bone. However, changes
in the synovium also occur. Small studies have described
synovial mononuclear cell inﬁltration in approximately 50%
of patients with both early and end stage disease21e23.
Smith et al. suggested that synovitis is more characteristic
of end stage disease26, while Benito and colleagues ob-
served that CD4þ and CD68þ inﬁltrates may be even
more pronounced in early OA27. The deﬁnition of early
OA and synovitis in these reports differs, perhaps leading
to the divergent conclusions. Although the majority of pa-
tients in the current study were undergoing joint arthroplasty
for advanced disease, 57% of all the patients with OA had
evidence of histologic synovitis regardless of whether dis-
ease was classiﬁed as advanced or early. This is consistent
with data from the majority of reports as well as the large-
scale retrospective review of 755 patients done to assess
our synovial grading system.
Assessing the prevalence of synovitis is difﬁcult due to
the possibility of sampling error. Arthroscopic and histologic
studies have shown that synovitis is more focal in OA com-
pared to RA, speciﬁcally more pronounced in the juxtachon-
dral regions28. A strength of this study is that we
systematically sampled synovium from a standard juxta-
chondral area. With this standardized sampling method,
we saw no signiﬁcant differences in the prevalence of syno-
vial inﬂammation in knee OA regardless of the actual
520 A. D. Pearle et al.: Synovial Inﬂammation and hsCRP in OAcompartmental localization of disease (data not shown).
Furthermore, there were no differences in the prevalence
of inﬁltrates according to KeL scores. This suggests that sy-
novial inﬂammation may identify an OA subset rather than
merely reﬂect a stage of disease progression.
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Fig. 2. (A) hsCRP levels in 52 OA patients with synovial inﬂamma-
tion compared to those without inﬂammation. Synovial inﬂammation
was deﬁned as having either low-grade or high-grade synovial lym-
phocytic inﬁltrates as described in Fig. 1. Mean standard deviation
(SD) in patients without inﬂammation was 1.7 3.6 mg/L, while in
those with inﬂammation it was 4.7 5.0 mg/L (P¼ 0.001). (B) Syno-
vial ﬂuid IL-6 levels in 25 advanced OA patients with synovial inﬂam-
mation compared to those without inﬂammation. In patients without
inﬂammation mean IL-6 was 41 42 pg/ml, while in those with in-
ﬂammation it was 141 169 pg/ml (P¼ 0.07, ns). (C) BMI in pa-
tients with and without synovial inﬂammation. Median (interquartile
range) BMI in patients without synovial inﬂammation was 27.45
(24.80e32.63). In patients with synovial inﬂammation median BMI
was 29.63 (25.40e34.26, P¼ 0.25) including an outlier with BMI
of 60.45, and 29.05 (25.40e33.87, P¼ 0.3) excluding this outlier.
This outlier was included in all analyses, as its exclusion did not
change any results signiﬁcantly.There is an increasing literature suggesting that synovitis
may contribute to symptoms and to cartilage damage in pa-
tients with OA. At least two studies have demonstrated that
magnetic resonance imaging (MRI) evidence of synovitis is
associated with pain in knee OA29,30. Most interestingly,
a prospective arthroscopic study of 420 patients with pri-
mary medial compartment knee OA demonstrated that pa-
tients with synovitis had more chondropathy at baseline,
and more progressive cartilage loss after 1 year31. On the
molecular level, serum hyaluronic acid, believed to originate
primarily from inﬂamed synovium, is elevated in OA and
correlates with a functional capacity score32. Otterness
et al. investigated the use of disease markers as a means
to distinguish the presence of OA33. They demonstrated
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Fig. 3. (A) Synovial ﬂuid IL-6 levels in advanced OA patients with
low (3 mg/ml) vs high (>3 mg/ml) hsCRP levels. Those in the
low hsCRP group had a meanSD IL-6 level of 35 45 pg/ml,
compared with 207 þ 177 pg/ml in the high hsCRP group
(P¼ 0.001). (B) Correlation of plasma hsCRP levels, and synovial
ﬂuid IL-6 levels. Statistical analysis yielded a Spearman r¼ 0.64
and P¼ 0.0006. Due to the non-Gaussian distribution, data were
plotted on log-10 axes. 0.6 was added prior to log transformation
to account for zero values.
Table III
Spearman correlations of hsCRP levels with synovial fluid IL-6,
histology, and clinical parameters
n Correlation coefﬁcient (r) P-value
Synovial ﬂuid IL-6 25 0.64 0.0006
Inﬂammatory grade 52 0.42 0.002
Body mass index 52 0.31 0.02
KellgreneLawrence score 43 0.07 0.67
Age 52 0.09 0.5
521Osteoarthritis and Cartilage Vol. 15, No. 5that inﬂammatory molecular markers deﬁned signiﬁcant dif-
ferences between patients with OA and control populations.
We observed that increasing degree of synovial inﬁltra-
tion correlated with elevated plasma hsCRP levels in idio-
pathic OA patients. This suggests that the elevated
hsCRP levels seen in these patients may reﬂect local in-
ﬂammation within the joint. Both in vitro and in vivo studies
have demonstrated that IL-6 is the chief regulator of CRP
production by hepatocytes34,35. Therefore, we assessed
IL-6 levels in both joint ﬂuid and plasma to evaluate this po-
tential molecular link between local synovitis and CRP pro-
duction. In the subset of patients with advanced OA from
whom we had joint ﬂuid, we found consistently detectable
levels of IL-6 in the synovial ﬂuid, but very low or undetect-
able levels in plasma consistent with previous reports35e37.
In addition, we observed a correlation between synovial
ﬂuid IL-6 levels and systemic hsCRP levels (r¼ 0.64,
P¼ 0.0006). Given the known mechanistic relationship be-
tween CRP and IL-6, this suggests that IL-6 produced in the
affected joint may in part be responsible for the elevations in
systemic hsCRP seen in this population of patients. Studies
in inﬂammatory arthritis have demonstrated an association
between synovial ﬂuid IL-6 levels and circulating levels of
CRP36, however, in idiopathic OA this association has not
been previously reported. It has been proposed that IL-6
produced at local sites is cleared rapidly from the circula-
tion38, and may accumulate within the liver to induce an
acute-phase protein response39. It is possible that this
mechanism is active in both a subset of OA and inﬂamma-
tory arthritis.
Another potential stimulus of CRP production by hepato-
cytes is IL-1. This cytokine appears to work synergistically
with IL-6 to promote CRP production in vitro40. IL-1 is pro-
duced by synovium and cartilage of patients with OA, and
is thought to play a central role in promoting articular carti-
lage catabolism41. We found no association between syno-
vial ﬂuid IL-1b levels and either hsCRP levels or synovial
inﬂammation grade. It is possible that other factors prevent
IL-1 from inﬂuencing CRP production in vivo, in contrast to
our prediction based on in vitro data.
Many cell types within the joint are capable of producing
IL-6 including synovial ﬁbroblasts42,43, synovial T cells44,
and articular chondrocytes45. The present study does not
address which cell type(s) is the predominant source, but
we did observe a correlation between synovial ﬂuid IL-6
and inﬂammatory cell inﬁltrates. This suggests that in this
group of patients, the majority of the IL-6 is produced by
the inﬂammatory cells themselves, or synovial ﬁbroblasts
activated by the inﬂammatory cells. A recently published
study of 51 RA patients undergoing knee surgery found
similar associations of synovial ﬂuid IL-6 levels and synovial
inﬂammatory inﬁltration46, consistent with the results pre-
sented here. These same associations found in a disease
long considered noninﬂammatory and fundamentally differ-
ent from RA is of considerable interest.
It is well known that hsCRP levels may be inﬂuenced by
age and obesity5. As expected, we observed a correlation
between hsCRP levels and BMI in patients with OA, consis-
tent with results from large studies of cardiovascular
risk25,47. However, our multivariate analysis suggests that
our results are unlikely to be attributable to weight alone,
as only synovial inﬂammatory grade was signiﬁcantly asso-
ciated with hsCRP levels. We saw no association between
BMI and degree of inﬂammation, and the nonsigniﬁcant
trend toward increased BMI in patients with synovial inﬁl-
trates could largely be explained by one outlier. Further-
more, we saw no association between systemic IL-6levels and either hsCRP (r¼ 0.09, P¼ 0.56) or BMI
(r¼0.004, P¼ 0.97) in this group of patients.
We did not observe a correlation between age and
hsCRP levels in our patients, in contrast to many epidemi-
ological studies. The association of age with hsCRP levels
may be indirect through various comorbid conditions (ex-
cluded in this study) that also increase with age. In spite
of the potential pathogenic mechanisms of OA that have
been identiﬁed in this study, this nonspeciﬁcity of CRP limits
its clinical utility as a disease marker.
In conclusion, we have identiﬁed a relationship among ele-
vated plasma levels of hsCRP, elevated synovial ﬂuid levels
of IL-6 and the presence of chronic synovial inﬂammation in
patients with idiopathic OA. Taken together with results
from studies linking elevated hsCRPwith more rapid disease
progression and pain, these data suggest that OA patients
with synovial inﬂammation and elevated hsCRP may form
a subgroup of patients with a more aggressive form of dis-
ease. In addition to the complex interactions between biome-
chanics and altered cartilage metabolism that initiate OA,
synovial inﬂammation may be an additional mechanism con-
tributing to disease pathogenesis in a subset of patients. Elu-
cidation of the cellular mechanisms that account for IL-6
production and inﬂammation in the synovial membrane of
some OA patients may add to our understanding of patho-
genesis and allow identiﬁcation of patients who may beneﬁt
most from more aggressive antiinﬂammatory therapy.
Acknowledgments
The authors would like to thank Bernard Ghelman, M.D. for
his assistance with the radiographic assessments, and
Stephen A. Paget, M.D. for his editorial assistance.
References
1. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T,
Sasiela WJ, Tsai J, et al. Statin therapy, LDL choles-
terol, C-reactive protein, and coronary artery disease.
N Engl J Med 2005;352:29e38.
2. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM,
McCabe CH, et al. C-reactive protein levels and out-
comes after statin therapy. N Engl J Med 2005;352:
20e8.
3. Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y,
Sakaguchi M, Nagai Y, et al. C-reactive protein is an
independent predictor of the rate of increase in early
carotid atherosclerosis. Circulation 2001;104:63e7.
4. Rossi E, Biasucci LM, Citterio F, Pelliccioni S,
Monaco C, Ginnetti F, et al. Risk of myocardial infarc-
tion and angina in patients with severe peripheral
vascular disease: predictive role of C-reactive protein.
Circulation 2002;105:800e3.
5. Ridker PM. High-sensitivity C-reactive protein: potential
adjunct for global risk assessment in the primary
prevention of cardiovascular disease. Circulation
2001;103:1813e8.
6. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A,
Kutys R, et al. Elevated C-reactive protein values
and atherosclerosis in sudden coronary death: associ-
ation with different pathologies. Circulation 2002;105:
2019e23.
7. Du Clos TW, Mold C. C-reactive protein: an activator of
innate immunity and a modulator of adaptive immunity.
Immunol Res 2004;30:261e77.
522 A. D. Pearle et al.: Synovial Inﬂammation and hsCRP in OA8. Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW. C-
reactive protein mediates protection from lipopolysac-
charide through interactions with Fc gamma R.
J Immunol 2002;169:7019e25.
9. Labarrere CA, Zaloga GP. C-reactive protein: from inno-
cent bystander to pivotal mediator of atherosclerosis.
Am J Med 2004;117:499e507.
10. Ballou SP, Lozanski G. Induction of inﬂammatory cyto-
kine release from cultured human monocytes by C-re-
active protein. Cytokine 1992;4:361e8.
11. Pasceri V, Chang J, Willerson JT, Yeh ETH. Modulation
of C-reactive protein-mediated monocyte chemoat-
tractant protein-1 induction in human endothelial cells
by anti-atherosclerosis drugs. Circulation 2001;103:
2531e4.
12. Wolfe F. The C-reactive protein but not erythrocyte sed-
imentation rate is associated with clinical severity in
patients with osteoarthritis of the knee or hip. J Rheu-
matol 1997;8:1486e8.
13. Conrozier T, Carlier MC, Mathieu P, Colson F,
Debard AL, Richard S, et al. Serum levels of YKL-40
and C reactive protein in patients with hip osteoarthritis
and healthy subjects: a cross sectional study. Ann
Rheum Dis 2000;59:828e31.
14. Sowers M, Jannausch M, Stein E, Jamadar D,
Hochberg M, Lachance L. C-reactive protein as
a biomarker of emergent osteoarthritis. Osteoarthritis
Cartilage 2002;10:595e601.
15. Sturmer T, Brenner H, Koenig W, Gunther KP. Severity
and extent of osteoarthritis and low grade systemic in-
ﬂammation as assessed by high sensitivity C reactive
protein. Ann Rheum Dis 2004;63:200e5.
16. Verhave JC, Hillege HL, Burgerhof JG, Gansevoort RT,
de Zeeuw D, de Jong PE. The association between
atherosclerotic risk factors and renal function in the
general population. Kidney Int 2005;67:1967e73.
17. Conrozier T, Chappuis-Cellier C, Richard M, Mathieu P,
Richard S, Vignon E. Increased serum C-reactive pro-
tein levels by immunonephelometry in patients with
rapidly destructive hip osteoarthritis. Rev Rhum Engl
Ed 1998;65:759e65.
18. Sharif M, Shepstone L, Elson CJ, Dieppe PA, Kirwan JR.
Increased serum C reactive protein may reﬂect events
that precede radiographic progression in osteoarthritis
of the knee. Ann Rheum Dis 2000;59:71e4.
19. Altman R, Asch E, Bloch D, Bole G, Borenstein D,
Brandt K, et al. Development of criteria for the classi-
ﬁcation and reporting of osteoarthritis. Classiﬁcation
of osteoarthritis of the knee. Diagnostic and Therapeu-
tic Criteria Committee of the American Rheumatism
Association. Arthritis Rheum 1986;29:1039e49.
20. Kellgren JH, Lawrence JS. Radiological assessment of
osteoarthrosis. Ann Rheum Dis 1957;16:494e502.
21. Myers SL, Brandt KD, Ehlich JW, Braunstein EM,
Shelbourne KD, Heck DA, et al. Synovial inﬂammation
in patients with early osteoarthritis of the knee.
J Rheumatol 1990;17:1662e9.
22. Revell PA, Mayston V, Lalor P, Mapp P. The synovial
membrane in osteoarthritis: a histological study includ-
ing the characterisation of the cellular inﬁltrate present
in inﬂammatory osteoarthritis using monoclonal anti-
bodies. Ann Rheum Dis 1988;47:300e7.
23. Goldenberg D, Egan M, Cohen A. Inﬂammatory synovi-
tis in degenerative joint disease. J Rheumatol 1982;9:
204e9.
24. Kraus VB, Huebner JL, Fink C, King JB, Brown S,
Vail TP, et al. Urea as a passive transport marker forarthritis biomarker studies. Arthritis Rheum 2002;46:
420e7.
25. Godefroi R, Klementowicz P, Pepler C, Lewis B,
McDonough K, Goldberg RJ. Levels of, and factors as-
sociated with, C-reactive protein in employees attend-
ing a company-sponsored cardiac screening program.
Cardiology 2005;103:180e4.
26. Smith MD, Triantaﬁllou S, Parker A, Youssef PP,
Coleman M. Synovial membrane inﬂammation and
cytokine production in patients with early osteoarthritis.
J Rheumatol 1997;24:365e71.
27. Benito MJ, Veale DJ, Fitzgerald O, van den Berg WB,
Bresnihan B. Synovial tissue inﬂammation in early
and late osteoarthritis. Ann Rheum Dis 2005;64:
1263e7.
28. Lindblad S, Hedfors E. Arthroscopic and immunohisto-
logic characterization of knee joint synovitis in osteoar-
thritis. Arthritis Rheum 1987;30:1081e8.
29. Hill CL, Gale DG, Chaisson CE, Skinner K, Kazis L,
Gale ME, et al. Knee effusions, popliteal cysts, and sy-
novial thickening: association with knee pain in osteo-
arthritis. J Rheumatol 2001;28:1330e7.
30. Torres L, Dunlop DD, Peterfy C, Guermazi A, Prasad P,
Hayes KW, et al. The relationship between speciﬁc
tissue lesions and pain severity in persons with knee
osteoarthritis. Osteoarthritis Cartilage 2006;14:1033e40.
31. Ayral X, Pickering EH, Woodworth TG, Mackillop N,
Dougados M. Synovitis: a potential predictive factor
of structural progression of medial tibiofemoral knee
osteoarthritis e results of a 1 year longitudinal arthro-
scopic study in 422 patients. Osteoarthritis Cartilage
2005;13:361e7.
32. Goldberg RL, Huff JP, Lenz ME, Glickman P, Katz R,
Thonar EJ. Elevated plasma levels of hyaluronate in
patients with osteoarthritis and rheumatoid arthritis.
Arthritis Rheum 1991;34:799e807.
33. Otterness IG, Swindell AC, Zimmerer RO, Poole AR,
Ionescu M, Weiner E. An analysis of 14 molecular
markers for monitoring osteoarthritis: segregation of
the markers into clusters and distinguishing osteoar-
thritis at baseline. Osteoarthritis Cartilage 2000;8:
180e5.
34. Gabay C, Kushner I. Acute-phase proteins and other
systemic responses to inﬂammation. N Engl J Med
1999;340:448e54.
35. Bhardwaj N, Santhanam U, Lau LL, Tatter SB,
Ghrayeb J, Rivelis M, et al. IL-6/IFN-beta 2 in synovial
effusions of patients with rheumatoid arthritis and
other arthritides. Identiﬁcation of several isoforms
and studies of cellular sources. J Immunol 1989;143:
2153e9.
36. Swaak AJ, van Rooyen A, Nieuwenhuis E, Aarden LA.
Interleukin-6 (IL-6) in synovial ﬂuid and serum of pa-
tients with rheumatic diseases. Scand J Rheumatol
1988;17:469e74.
37. Uson J, Balsa A, Pascual-Salcedo D, Cabezas JA,
Gonzalez-Tarrio JM, Martin-Mola E, et al. Soluble in-
terleukin 6 (IL-6) receptor and IL-6 levels in serum
and synovial ﬂuid of patients with different arthropa-
thies. J Rheumatol 1997;24:2069e75.
38. Castell JV, Geiger T, Gross V, Andus T, Walter E,
Hirano T, et al. Plasma clearance, organ distribu-
tion and target cells of interleukin-6/hepatocyte-
stimulating factor in the rat. Eur J Biochem 1988;
177:357e61.
39. McNiff PA, Stewart C, Sullivan J, Showell HJ,
Gabel CA. Synovial ﬂuid from rheumatoid arthritis
523Osteoarthritis and Cartilage Vol. 15, No. 5patients contains sufﬁcient levels of IL-1 beta and IL-6
to promote production of serum amyloid A by Hep3B
cells. Cytokine 1995;7:209e19.
40. Zhang D, Jiang SL, Rzewnicki D, Samols D, Kushner I.
The effect of interleukin-1 on C-reactive protein ex-
pression in Hep3B cells is exerted at the transcrip-
tional level. Biochem J 1995;310(Pt 1):143e8.
41. Abramson SB, Attur M, Amin AR, Clancy R. Nitric
oxide and inﬂammatory mediators in the perpetuation
of osteoarthritis. Curr Rheumatol Rep 2001;3:
535e41.
42. HwangSY,KimJY,KimKW,ParkMK,MoonY,KimWW,
et al. IL-17 induces production of IL-6 and IL-8 in rheu-
matoid arthritis synovial ﬁbroblasts via NF-kappaB-
and PI3-kinase/Akt-dependent pathways. Arthritis Res
Ther 2004;6:R120e8.
43. Fiorito S, Magrini L, Adrey J, Mailhe D, Brouty-Boye D.
Inﬂammatory status and cartilage regenerative poten-
tial of synovial ﬁbroblasts from patients withosteoarthritis and chondropathy. Rheumatology (Ox-
ford) 2005;44:164e71.
44. Wood NC, Symons JA, Dickens E, Duff GW. In situ
hybridization of IL-6 in rheumatoid arthritis. Clin Exp
Immunol 1992;87:183e9.
45. Fan Z, Bau B, Yang H, Aigner T. IL-1beta induction of
IL-6 and LIF in normal articular human chondrocytes
involves the ERK, p38 and NFkappaB signaling path-
ways. Cytokine 2004;28:17e24.
46. Matsumoto T, Tsurumoto T, Shindo H. Interleukin-6
levels in synovial ﬂuids of patients with rheumatoid ar-
thritis correlated with the inﬁltration of inﬂammatory
cells in synovial membrane. Rheum Int 2006;26:
1096e100.
47. Aronson D, Goldberg A, Roguin A, Petcherski S,
Rimer D, Gruberg L, et al. Effect of obesity on the re-
lationship between plasma C-reactive protein and cor-
onary artery stenosis in patients with stable angina.
Atherosclerosis 2005;185:137e42.
